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Abstract 
 
In different native tissues and cells the receptor for the vasodepressor bradykinin, B2, 
forms dimers with the receptor for the vasopressor angiotensin II, AT1. Because AT1/B2 
heterodimers may contribute to enhanced angiotensin II-stimulated signalling under 
pathophysiological conditions, we analyzed mechanisms of AT1/B2 heterodimerization. 
We found that efficient B2 receptor maturation was a prerequisite for 
heterodimerization because only the fully mature B2 receptor was capable to interact 
with AT1. To identify chaperones involved in B2 receptor maturation and 
heterodimerization we performed microarray gene expression profiling of human 
embryonic kidney (HEK293) cells. The expression of the chaperone calreticulin was up-
regulated in cells with efficient B2 receptor maturation. Vice versa, upon down 
regulation of calreticulin expression by RNA interference, B2 receptor maturation and 
AT1/B2 receptor heterodimerization were significantly impaired. Concomitantly, the B2 
receptor-mediated enhancement of AT1-stimulated signalling was reduced. Thus, 
calreticulin enhances B2 receptor maturation and heterodimerization with AT1.  
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Introduction 
 
 Angiotensin II is an important peptide hormone regulating vascular tone and blood 
pressure. The vasopressor actions of angiotensin II are mediated mainly by the AT1 receptor. 
In contrast, bradykinin is a vasodepressor peptide, which exerts major effects via the B2 
bradykinin receptor. The angiotensin II and bradykinin systems are intertwined at multiple 
levels. The angiotensin-converting enzyme (ACE) regulates the availability of both peptides 
in vivo by releasing angiotensin II and inactivating bradykinin. With more than 30% identity, 
the AT1 receptor is one of the closest relatives of the B2 receptor. In agreement with the high 
homology, a direct interaction between the angiotensin II AT1 receptor and the bradykinin B2 
receptor in vivo in rat brain is known since 1993 [1]. We followed those original studies, and 
identified AT1/B2 receptor heterodimers in different other native systems and in patients with 
preeclampsia [2,3]. In addition to the in vivo data, AT1/B2 interactions were also reconstituted 
in a transfected in vitro system [2,3].  
 Heterodimerization of AT1 with B2 receptors leads to signal enhancement of AT1 
[2,3]. Signal enhancement as a consequence of heterodimerization with the B2 receptor is also 
effective for the closely related angiotensin II AT2 receptor [4]. Both studies were performed 
with native cells [3,4]. Thus, a native, correctly folded B2 receptor protein seems to be 
required for receptor heterodimerization and signal enhancement. 
  For various G-protein-coupled receptors, conditions of efficient protein 
folding were investigated. Different chaperones are known to be involved in the correct 
folding of AT1 receptors such as BiP, calnexin, and D1RiP78 [5]. By contrast, little is known 
about chaperones, which assist the folding of B2 receptors and AT1/B2 receptor 
heterodimerization. We therefore analyzed requirements for efficient B2 receptor maturation 
and the potential interrelationship between B2 receptor maturation and heterodimerization 
with the angiotensin II AT1 receptor.  
 
Materials and methods 
 
 Cell culture and cell transfection. HEK293 cells cells were routinely grown in 
DMEM (100 mg/dl glucose) supplemented with 10 % (v/v) FCS unless otherwise indicated. 
Cells were transfected with Lipofectamine Plus (Invitrogen). Transfection efficiency of 
HEK293 cells was ≥90 %. Plasmids encoding the human B2 and AT1 receptor under control 
of the CMV promoter were used. Cellular inositol phosphate levels were determined 
similarly as described [2]. For down-regulation of calreticulin expression, HEK293 cells were 
transfected with stealth RNAi (20 pmol/ml) targeting the coding sequence of the human 
calreticulin cDNA (nucleotides 59-83, RNAi-Calreticulin1 and nucleotides 367-391, RNAi-
Calreticulin2). Quantification of B2 receptors was performed on HEK cells with 50 nM of 
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[125I]-labeled F(ab)2 fragments of affinity-purified B2 receptor-specific antibodies (~1 µCi) 
similarly as described [6].  
 Protein detection in immunoblot and co-enrichment of receptors. Protein detection in 
immunoblot was performed with membranes prepared by sucrose density gradient 
centrifugation followed by partial enrichment as described [2]. For co-enrichment of AT1 and 
B2 receptors, membranes of HEK cells were solubilized with RIPA buffer (including protease 
inhibitor cocktail) and subjected to immuno-affinity chromatography by anti-AT1 receptor 
antibodies using 0.1 ml immunoaffinity matrix (Affigel 10; 15 mg affinity-purified antibodies 
per ml gel). After extensive washing, proteins were eluted with 0.2 M glycine, pH 2.5, 
neutralized, desalted, delipidated and precipitated [2]. Eluted proteins were dissolved and 
separated by urea-containing SDS-PAGE under reducing conditions. Enriched AT1 and co-
enriched B2 receptors were identified in immunoblot with F(ab)2 fragments of the respective 
anti-receptor antibodies. Enrichment of the B2 receptor was performed analogously with anti-
B2 receptor antibodies. Chemical deglycosylation of the enriched B2 receptor was performed 
with trifluoromethanesulfonic acid (TFMS) at 0 °C as described [7].  
 Cross-linking of bradykinin to the B2 receptor. Cross-linking of bradykinin (5 nM) to 
the B2 receptor was performed with 0.2 mM m-maleimidobenzoyl-N-hydroxysuccinimide 
ester (MBS) in the absence or presence of a 400-fold molar excess of the B2-specific 
antagonist HOE140 at 4 °C using membranes prepared from B2 receptor-expressing HEK293 
cells as described previously [2,8]. Solubilized proteins were separated by SDS-PAGE under 
reducing conditions including 6 M urea followed by immunoblotting with anti-bradykinin 
antibodies [2]. 
 Antibodies used for immunoblotting and immunofluorescence. All antibodies used for 
immunoblotting, receptor immunoaffinity enrichment and immunofluorescence were 
characterized in previous studies [2,3,6,8-10]. Immunofluorescence was performed with 
paraformaldehyde-fixed (4 % w/v) cells [6]. 
 Microarray gene expression profiling. For microarray gene expression analysis, 
HEK293 cells were cultivated for 7 days in DMEM supplemented with 10 % FCS and 100 
mg/dl (low) or 450 mg/dl (high) glucose. Total RNA was isolated with the RNeasy Mini kit 
(Qiagen). Procedures for cDNA synthesis, labeling and hybridization were carried out 
according to the protocol of the manufacturer (Affymetrix GeneChip Expression Analysis 
Technical Manual; Rev. 5). For hybridization, 15 µg of fragmented cRNA were incubated 
with the chip (Affymetrix GeneChip Human genome U133 Plus 2.0 Array) in 200 µl of 
hybridization solution in a Hybridization Oven 640 (Affymetrix) at 45 °C for 16 h. 
GeneChips were then washed and stained using the Affymetrix Fluidics Station 450. 
Microarrays were scanned with the Affymetrix GeneChip Scanner 7G, and the signals were 
processed using GCOS (v. 1.4, Affymetrix). Gene expression data are available at GEO 
accession no GSE15575.  
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 Statistics. Unless otherwise stated, data are expressed as mean ± S.E. To determine 
significance between two groups, we made comparisons using the unpaired two-tailed 
Student`s t-test. P values of < 0.05 were considered significant. 
 
Results 
 
Transfected HEK293 cells synthesize a monomeric B2 receptor that resembles the native B2 
receptor protein  
 
 Protein maturation was assessed with HEK293 cells as an expression system because 
the B2 receptor protein of transfected HEK293 cells appeared as a pure monomer (Fig. 1A). 
Even at high receptor expression levels (>5 pmol/mg protein), the B2 receptor expressed in 
HEK293 cells did not show significant protein aggregation under reducing conditions of 
SDS-PAGE supplemented with urea (Fig. 1A). The B2 receptor protein of transfected 
HEK293 cells showed a similar apparent molecular mass in SDS-PAGE as the native B2 
receptor protein of various native tissues and cells (Fig. 1B). Detection of the B2 receptor by 
immunofluorescence revealed the predominant membrane localization of the transfected B2 
receptor on HEK293 cells (Fig. 1C). Altogether, these findings indicate that HEK293 cells 
express all the proteins necessary for efficient B2 receptor folding. 
   
High glucose induces an immature B2 receptor protein in HEK293 cells 
 
 Expression of mature and correctly folded receptors on the plasma membrane depends 
on the general chaperone system of the endoplasmic reticulum (ER) controlling protein 
synthesis, folding and assembly [11]. To assess the impact of the general chaperone system 
on B2 receptor folding and AT1/B2 receptor heterodimerization, we down-regulated the 
general chaperone system of HEK293 cells by high glucose [12]. Cultivation of HEK293 
cells in a standard medium with high glucose (450 mg/dl) led to the appearance of an 
"immature" B2 receptor-reactive band of ~53 ± 4 kDa in addition to the (mature) B2 receptor 
of 67 ± 5 kDa (Fig. 2A). 
 The B2 receptor-reactive band of 53 kDa did not show a high-affinity interaction with 
the agonist bradykinin as assessed by affinity cross-linking (Fig. 2B). Chemical 
deglycosylation of the "mature" and "immature" B2 receptor proteins produced the 
deglycosylated B2 receptor of  ~ 43 kDa (Fig. 2C). These experiments strongly suggest that 
the 53 kDa protein is indeed an immature B2 receptor which is not fully glycosylated. 
Interestingly, the immature B2 receptor of 53 kDa did not interact with the AT1 receptor as 
assessed by co-immunoenrichment (Fig. 2D). Thus, efficient B2 receptor maturation seems to 
be required for heterodimerization with the AT1 receptor. 
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Microarray gene expression profiling of the general chaperone system of HEK293 cells 
 
 To determine chaperone(s) involved in B2 receptor maturation and AT1/B2 receptor 
heterodimerization, we performed microarray gene expression profiling of HEK293 cells 
cultivated in low and high glucose medium, respectively. Differentially expressed proteins of 
the ER protein quality-control system were identified by selection of probe sets with (i) ≥ 2.5-
fold higher expression in low versus high glucose, (ii) ER localization according to gene 
ontology (GO) analysis, and (iii) involvement in the general chaperone system according to 
the literature (Fig. 3A). The approach identified 14 ER-localized members of the protein 
quality-control system that showed a more than 2.5-fold higher expression signal in cells 
cultivated in low glucose relative to high glucose (Fig. 3A). The microarray gene expression 
data were verified by immunoblotting as exemplified for GRP78 (Fig. 3B). 
 
The chaperone calreticulin co-localizes with the B2 receptor  
 
 Several of the identified proteins of the general chaperone system are reported to be 
involved in folding of membrane proteins [5]. Searching for chaperones that are specifically 
required for the maturation of B2 receptors, we focused on calreticulin, because gene 
inactivation studies revealed an interrelationship between calreticulin and functional B2 
receptor protein levels [13]. Immunoblotting confirmed the microarray-based evidence of a 
significantly higher calreticulin protein expression in HEK293 cells cultivated in low glucose 
relative to high glucose (Fig. 3B, middle panel). As a control, actin protein levels of HEK293 
cells were not significantly different (Fig. 3B, lower panel). In agreement with a potential 
role of calreticulin in B2 receptor folding and maturation, immunofluorescence revealed the 
cellular co-localization of the B2 receptor with calreticulin (Fig. 3C). 
 
Down-regulation of calreticulin expression by RNA interference impairs B2 receptor 
maturation and AT1/B2 receptor heterodimerization 
 
 To determine the potential involvement of calreticulin in B2 receptor maturation, we 
down-regulated the expression of calreticulin by RNA interference. Upon down-regulation of 
calreticulin, the maturation of the B2 receptor protein was significantly affected as evidenced 
by the appearance of the immature B2 receptor protein band of 53 kDa even when cells were 
cultivated in a medium with a physiological (low) glucose concentration (Fig. 4A). 
 Moreover, down-regulation of calreticulin strongly reduced the AT1/B2 receptor 
interaction because only the fully mature B2 receptor of 67 kDa was capable to interact with 
AT1 whereas the immature B2 receptor of 53 kDa was not significantly co-enriched with AT1 
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(Fig. 4B). Concomitantly, the B2 receptor-mediated enhancement of the AT1-stimulated 
signal - an additional indicator of AT1/B2 receptor heterodimerization - was strongly 
decreased upon down-regulation of calreticulin (Fig. 4C). Together these data suggest that 
endogenous calreticulin expression levels of HEK293 cells are sufficient to enhance B2 
receptor maturation and AT1/B2 receptor heterodimerization. 
 
Discussion 
 
 In various in vivo systems the receptor for the vasodepressor bradykinin, B2, 
undergoes a functional interaction with the receptor for the vasopressor angiotensin II, AT1 
[1-3,14]. The covalently bonded AT1/B2 receptor heterodimers are distinguished from 
individual, dissociable receptors by a kinetically favored interaction with G-proteins leading 
to enhanced AT1-stimulated signaling [2-3]. Because increased formation of AT1/B2 receptor 
heterodimers could constitute a pathological feature of hypertensive disorders [3,14], the 
current study investigated mechanisms required for functional AT1/B2 receptor 
heterodimerization. 
 Several lines of evidence are presented supporting that efficient protein maturation of 
the B2 receptor is a prerequisite for functional interaction with AT1. First, only the mature B2 
receptor interacted with co-expressed AT1 as determined by co-enrichment. Second, 
microarray gene expression profiling revealed a correlation between efficient AT1/B2 receptor 
heterodimerization and the expression of the general chaperone system. Finally, RNA 
interference studies determined the involvement of the chaperone calreticulin in B2 receptor 
maturation and AT1/B2 receptor heterodimerization. Future studies will have to assess 
whether the herein identified requirement of specific chaperone(s) for AT1/B2 receptor 
heterodimerization is a factor involved in the induction of AT1/B2 receptor heterodimers 
under pathophysiological conditions. 
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Figure legends 
 
Fig. 1. (A) Immunoblot detection of the B2 receptor (IB: anti-B2) with F(ab)2 fragments of 
affinity-purified B2-specific antibodies on enriched membranes of HEK293 cells (HEK) 
expressing ~ 5 pmol B2 receptor/mg protein (lane 1). As a control, AT1 receptor-expressing 
HEK cells were used (lane 2). (B) Immunoblot detection of B2 receptors on the enriched and 
acetone-precipitated, solubilized membrane fraction prepared from different native tissues, 
i.e. human umbilical vein endothelial cells (HUVEC; lane 1), prostate cancer tissue (Prost. 
canc., lane 2), bladder cancer tissue (Bladd. canc., lane 3), WI-38 fibroblasts (lane 4), and 
human skin fibroblasts (Skin-fibr., lane 5). (C) Immunofluorescence detection of the B2 
receptor on B2 receptor-transfected HEK293 cells (HEK/B2). The lower panel shows merged 
pictures of B2 receptor localization and DAPI-stained cell nuclei (anti-B2/DAPI). (Original 
magnification, 630 x).  
 
Fig. 2. (A) Immunoblot detection of the B2 receptor (IB: anti-B2) on enriched membranes of 
HEK293 cells (HEK/B2; expression of ~ 240 fmol B2/mg protein) cultivated in a medium 
with high (450 mg/dl) or low (100 mg/dl) glucose. (B) Affinity-crosslinking of bradykinin 
(Bk) to the B2 receptor expressed in HEK293 cells (HEK/B2) cultivated in medium with 450 
or 100 mg/dl glucose as indicated (450; 100), and detection of cross-linked bradykinin in 
immunoblot with affinity-purified anti-bradykinin antibodies (IB: anti-Bk). B2-specificity was 
assessed with the B2-specific antagonist HOE140 (2 µM; lanes 3,4). (C) Chemical 
deglycosylation (deglycosyl.) by TFMS (± TFMS) of enriched B2 receptors from HEK293 
cells (HEK/B2) cultivated in medium containing 100 or 450 mg/dl glucose followed by 
immunoblot detection of B2 (IB: anti-B2). (D) Immunoaffinity enrichment of the AT1 
receptor (± AP: AT1) from AT1 and B2 receptor co-expressing HEK293 cells (HEK/AT1-B2) 
cultivated in medium containing high glucose (450 mg/dl), and detection of co-enriched B2 
receptor or enriched AT1 receptor in immunoblot with F(ab)2 fragments of affinity-purified 
B2- or AT1-specific antibodies, respectively (lane 2, upper and lower panel). As a control, the 
solubilisate was applied for immunoblot detection of the B2 or AT1 receptor (lane 1, upper 
and lower panel). 
 
Fig. 3. (A) Microarray gene expression profiling of HEK293 cells (HEK). Probe sets of low 
glucose-cultivated HEK293 cells with a ≥ 2.5-fold increased signal relative to that of high 
glucose-cultivated HEK293 cells (Fold increase; low/high gluc.; t-test p value ≤ 0.01), ER 
localization and involvement in the general chaperone system are listed. (B) Immunoblot 
analysis controlling the microarray data. (C) Co-localization of the B2 receptor with 
calreticulin in HEK293 cells (HEK/B2-calreticulin) cultivated in low glucose medium. 
(Original magnification: 630 x). 
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Fig. 4. (A) Immunoblot detection of the B2 receptor (IB: anti-B2) expressed in HEK293 cells 
(HEK/B2) cultivated in low glucose (100 mg/dl). As indicated, membranes of control 
HEK/B2 cells (-; lane 1), of cells transfected with an unrelated control RNAi duplex (Cont-
RNAi; lane 2), or of cells transfected with two different RNAi duplexes targeting calreticulin 
by RNA interference (RNAi-Calret1, RNAi-Calret2; lanes 3,4) were applied. The lower panel 
shows an immunoblot of calreticulin (IB: anti-calreticulin). (B) Immuno-affinity enrichment 
of the AT1 receptor (± AP: AT1) from AT1 and B2 receptor co-expressing HEK293 cells 
(HEK/AT1-B2) transfected with an unrelated control RNAi duplex (Cont-RNAi; left panels) 
or an RNAi duplex targeting calreticulin by RNA interference (RNAi-Calret2; right panels), 
and detection of the co-enriched B2 receptor or enriched AT1 receptor in immunoblot with 
F(ab)2 fragments of affinity-purified B2- or AT1-specific antibodies, respectively (lanes 2/4, 
upper and lower panels). Lanes 1 and 3 show detection of the B2 or AT1 receptor in the 
solubilisate. (C) Strongly reduced B2 receptor-mediated enhancement of the angiotensin II-
stimulated (AngII, 100 nM) inositol phosphate signal upon down-regulation of calreticulin 
(columns 1,2). As a control, transfection of an unrelated control RNAi duplex (Cont-RNAi) 
did not impair the B2 receptor-mediated enhancement of the angiotensin II-stimulated inositol 
phosphate generation relative to control cells (Control) without RNAi duplex transfection 
(columns 3,4 versus 5,6). HEK293 cells expressed comparable levels of cell-surface receptors 
as determined with [125I]-labeled F(ab)2 fragments of affinity-purified B2- and AT1-specific 
antibodies (268 ± 9 fmol/mg protein of B2 receptor and 139 ± 8 fmol/mg protein of AT1 
receptor). Data represent mean ± S.E., n=3 (*p < 0.04; **p < 0.002). 
 
 




